Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group.

@article{Pfreundschuh1994DexaBEAMIP,
  title={Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group.},
  author={Michael Pfreundschuh and Ulrich Rueffer and Bernd Lathan and Norbert Schmitz and Oana Brosteanu and Dirk Hasenclever and Rainer Haas and Hartmut Kirchner and Peter Koch and Rolf Kuse},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1994},
  volume={12 3},
  pages={
          580-6
        }
}
PURPOSE A prospective phase II study was conducted to evaluate the efficacy of dexamethasone, carmustine, etoposide, cytarabine, and melphalan (Dexa-BEAM) as salvage chemotherapy for patients with Hodgkin's disease. PATIENTS AND METHODS Fifty-five patients progressing on or relapsing after eight- or 10-drug chemotherapy (cyclophosphamide, vincristine, procarbazine, and prednisone plus doxorubicin, bleomycin, vinblastine, and dacarbazine [COPP+ABVD] or COPP+ABV+ifosfamide, methotrexate… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 42 CITATIONS

Similar Papers

Loading similar papers…